DecisionDx-MelanomaDecember 21, 2017
In 2014, 76,665 Americans were diagnosed with melanoma of the skin and 9324 died from complications of their melanomas. The staging of melanoma is important to predict risk of recurrence and guide surveillance and treatment. Current guidelines for staging include evaluating: tumor thickness, ulceration, mitotic rate, regional lymph node status, metastasis, and lactate dehydrogenase level. Staging parameters provide some information of value in disease management, but there is wide variability in rates of metastasis even for cancers of the same stage. The development of tools that may provide more accurate information regarding metastasis risk is, therefore, an area of active interest. One such tool is the DecisionDx-Melanoma test, a multigene expression assay that is designed to predict distant metastasis in patients with stage I and II cutaneous melanoma.
If you have a Hayes login, click here to view the full report on the Knowledge Center.